Addressing Challenges in Prostate Cancer Management for the Elderly: The Role of Liquid Enzalutamide Formulations: A Review

Abstract

Polypharmacy due to various comorbidities in elderly prostate cancer patients causes inconvenience and may lead to compliance-related challenges. A higher incidence of dysphagia in such patients adds to the difficulty of ingesting large
capsules or tablets, including those of Enzalutamide. Liquid Enzalutamide, an oral suspension formulation, is likely to increase dosing convenience for elderly prostate cancer patients who are already burdened with polypharmacy. This
formulation of Enzalutamide oral suspension (Liquid Enzalutamide) is a new generation formulation that doesn’t contain the excipient ‘Labrasol,’ which is associated with diarrhoea, and instead contains Koliphor EL as a solubilizer.